U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Shortened PR interval

MedGen UID:
105466
Concept ID:
C0520878
Finding
Synonym: Short PR interval
SNOMED CT: Shortened PR interval (49578007)
 
HPO: HP:0005165

Definition

Reduced time for the PR interval (beginning of the P wave to the beginning of the QRS complex). In adults, normal values are 120 to 200 ms long. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVShortened PR interval

Conditions with this feature

Glycogen storage disease, type II
MedGen UID:
5340
Concept ID:
C0017921
Disease or Syndrome
Pompe disease is classified by age of onset, organ involvement, severity, and rate of progression. Infantile-onset Pompe disease (IOPD; individuals with onset before age 12 months with cardiomyopathy) may be apparent in utero but more typically onset is at the median age of four months with hypotonia, generalized muscle weakness, feeding difficulties, failure to thrive, respiratory distress, and hypertrophic cardiomyopathy. Without treatment by enzyme replacement therapy (ERT), IOPD commonly results in death by age two years from progressive left ventricular outflow obstruction and respiratory insufficiency. Late-onset Pompe disease (LOPD; including: (a) individuals with onset before age 12 months without cardiomyopathy; and (b) all individuals with onset after age 12 months) is characterized by proximal muscle weakness and respiratory insufficiency; clinically significant cardiac involvement is uncommon.
Wolff-Parkinson-White pattern
MedGen UID:
12162
Concept ID:
C0043202
Disease or Syndrome
Wolff-Parkinson-White syndrome is a condition characterized by abnormal electrical pathways in the heart that cause a disruption of the heart's normal rhythm (arrhythmia).\n\nThe heartbeat is controlled by electrical signals that move through the heart in a highly coordinated way. A specialized cluster of cells called the atrioventricular node conducts electrical impulses from the heart's upper chambers (the atria) to the lower chambers (the ventricles). Impulses move through the atrioventricular node during each heartbeat, stimulating the ventricles to contract slightly later than the atria.\n\nPeople with Wolff-Parkinson-White syndrome are born with an extra connection in the heart, called an accessory pathway, that allows electrical signals to bypass the atrioventricular node and move from the atria to the ventricles faster than usual. The accessory pathway may also transmit electrical impulses abnormally from the ventricles back to the atria. This extra connection can disrupt the coordinated movement of electrical signals through the heart, leading to an abnormally fast heartbeat (tachycardia) and other changes in heart rhythm. Resulting symptoms include dizziness, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, and fainting (syncope). In rare cases, arrhythmias associated with Wolff-Parkinson-White syndrome can lead to cardiac arrest and sudden death. The most common arrhythmia associated with Wolff-Parkinson-White syndrome is called paroxysmal supraventricular tachycardia.\n\nComplications of Wolff-Parkinson-White syndrome can occur at any age, although some individuals born with an accessory pathway in the heart never experience any health problems associated with the condition.\n\nWolff-Parkinson-White syndrome often occurs with other structural abnormalities of the heart or underlying heart disease. The most common heart defect associated with the condition is Ebstein anomaly, which affects the valve that allows blood to flow from the right atrium to the right ventricle (the tricuspid valve). Additionally, the heart rhythm problems associated with Wolff-Parkinson-White syndrome can be a component of several other genetic syndromes, including hypokalemic periodic paralysis (a condition that causes episodes of extreme muscle weakness), Pompe disease (a disorder characterized by the storage of excess glycogen), Danon disease (a condition that weakens the heart and skeletal muscles and causes intellectual disability), and tuberous sclerosis complex (a condition that results in the growth of noncancerous tumors in many parts of the body).
Hypertrophic cardiomyopathy 6
MedGen UID:
331466
Concept ID:
C1833236
Disease or Syndrome
Mutations in the PRKAG2 gene (602743) give rise to a moderate, essentially heart-specific, nonlysosomal glycogenosis with clinical onset typically in late adolescence or in the third decade of life, ventricular pre-excitation predisposing to supraventricular arrhythmias, mild to severe cardiac hypertrophy, enhanced risk of sudden cardiac death in midlife, and autosomal dominant inheritance with full penetrance (summary by Burwinkel et al., 2005).
Lethal congenital glycogen storage disease of heart
MedGen UID:
337919
Concept ID:
C1849813
Disease or Syndrome
A rare glycogen storage disease with fetal or neonatal onset of severe cardiomyopathy with non-lysosomal glycogen accumulation and fatal outcome in infancy. Patients present with massive cardiomegaly, severe cardiac and respiratory complications and failure to thrive. Non-specific facial dysmorphism, bilateral cataracts, macroglossia, hydrocephalus, enlarged kidneys and skeletal muscle involvement have been reported in some cases.
Lown-Ganong-Levine syndrome
MedGen UID:
354734
Concept ID:
C1862387
Disease or Syndrome
Lown-Ganong-Levine syndrome is an extremely rare conduction disorder characterized by a short PR interval (less than or equal to 120 ms) with normal QRS complex on electrocardiogram associated with the occurrence of episodes of atrial tachyarrythmias (e.g. atrial fibrillation, atrial tachycardia).
Progressive familial heart block type IB
MedGen UID:
370220
Concept ID:
C1970298
Disease or Syndrome
Most cases of heart block are not genetic and are not considered progressive familial heart block. The most common cause of heart block is fibrosis of the heart, which occurs as a normal process of aging. Other causes of heart block can include the use of certain medications or an infection of the heart tissue.\n\nProgressive familial heart block can be divided into type I and type II, with type I being further divided into types IA and IB. These types differ in where in the heart signaling is interrupted and the genetic cause. In types IA and IB, the heart block originates in the bundle branch, and in type II, the heart block originates in the atrioventricular node. The different types of progressive familial heart block have similar signs and symptoms.\n\nHeart block occurs when the electrical signaling is obstructed anywhere from the atria to the ventricles. In people with progressive familial heart block, the condition worsens over time: early in the disorder, the electrical signals are partially blocked, but the block eventually becomes complete, preventing any signals from passing through the heart. Partial heart block causes a slow or irregular heartbeat (bradycardia or arrhythmia, respectively), and can lead to the buildup of scar tissue (fibrosis) in the cells that carry electrical impulses. Fibrosis contributes to the development of complete heart block, resulting in uncoordinated electrical signaling between the atria and the ventricles and inefficient pumping of blood in the heart. Complete heart block can cause a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, fainting (syncope), or sudden cardiac arrest and death.\n\nProgressive familial heart block is a genetic condition that alters the normal beating of the heart. A normal heartbeat is controlled by electrical signals that move through the heart in a highly coordinated way. These signals begin in a specialized cluster of cells called the sinoatrial node (the heart's natural pacemaker) located in the heart's upper chambers (the atria). From there, a group of cells called the atrioventricular node carries the electrical signals to another cluster of cells called the bundle of His. This bundle separates into multiple thin spindles called bundle branches, which carry electrical signals into the heart's lower chambers (the ventricles). Electrical impulses move from the sinoatrial node down to the bundle branches, stimulating a normal heartbeat in which the ventricles contract slightly later than the atria.
Combined oxidative phosphorylation defect type 15
MedGen UID:
1646555
Concept ID:
C4706313
Disease or Syndrome
A rare mitochondrial disease due to a defect in mitochondrial protein synthesis with onset in infancy or early childhood of muscular hypotonia, gait ataxia, mild bilateral pyramidal tract signs, developmental delay (affecting mostly speech and coordination) and subsequent intellectual disability. Short stature, obesity, microcephaly, strabismus, nystagmus, reduced visual acuity, lactic acidosis, and a brain neuropathology consistent with Leigh syndrome are also reported. Caused by homozygous or compound heterozygous mutation in the MTFMT gene on chromosome 15q22.
Neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment
MedGen UID:
1823998
Concept ID:
C5774225
Disease or Syndrome
Neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment (NEDMVIC) is an autosomal recessive disorder characterized by global developmental delay, impaired intellectual development, facial dysmorphism, and microcephaly (Ziegler et al., 2022).

Professional guidelines

PubMed

Dusi V, Pugliese L, De Ferrari GM, Odero A, Crotti L, Dagradi F, Castelletti S, Vicentini A, Rordorf R, Li C, Shkolnikova M, Spazzolini C, Schwartz PJ
JACC Clin Electrophysiol 2022 Mar;8(3):281-294. Epub 2021 Oct 27 doi: 10.1016/j.jacep.2021.09.002. PMID: 35331422
Yan L, Huang H, Lin J, Yu R
Int J Hyperthermia 2022;39(1):230-238. doi: 10.1080/02656736.2022.2029956. PMID: 35094613
Rossello X, Wiegerinck RF, Alguersuari J, Bardají A, Worner F, Sutil M, Ferrero A, Cinca J
Am J Med 2014 Mar;127(3):233-9. Epub 2013 Nov 25 doi: 10.1016/j.amjmed.2013.11.006. PMID: 24287008

Recent clinical studies

Etiology

Nakamura S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nohara Y, Kono S, Nakao E, Sakaue A, Tsuru T, Morikawa N, Fukumoto Y
J Cardiol 2017 Oct;70(4):353-358. Epub 2017 Jan 18 doi: 10.1016/j.jjcc.2016.12.004. PMID: 28109825
Bohm P, Ditzel R, Ditzel H, Urhausen A, Meyer T
J Sports Sci 2013;31(13):1475-80. Epub 2013 Jun 17 doi: 10.1080/02640414.2013.796067. PMID: 23768165
Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ
Clin Endocrinol (Oxf) 2007 Feb;66(2):235-45. doi: 10.1111/j.1365-2265.2006.02715.x. PMID: 17223994
Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, Kanter RJ, Rice H, Chen YT, Kishnani PS
Genet Med 2006 May;8(5):297-301. doi: 10.1097/01.gim.0000195896.04069.5f. PMID: 16702879

Diagnosis

Coughlan JJ, Elkholy K, O'Brien J, Kiernan T
BMJ Case Rep 2016 Mar 17;2016 doi: 10.1136/bcr-2015-213819. PMID: 26989114Free PMC Article
Bohm P, Ditzel R, Ditzel H, Urhausen A, Meyer T
J Sports Sci 2013;31(13):1475-80. Epub 2013 Jun 17 doi: 10.1080/02640414.2013.796067. PMID: 23768165
Barold SS, Herweg B
Herzschrittmacherther Elektrophysiol 2012 Dec;23(4):296-304. Epub 2012 Dec 7 doi: 10.1007/s00399-012-0240-8. PMID: 23224264
Barold SS, Hayes DL
Mayo Clin Proc 2001 Jan;76(1):44-57. doi: 10.4065/76.1.44. PMID: 11155413
Denker ST, Gilbert CJ, Shenasa M, Akhtar M
J Electrocardiol 1983 Jul;16(3):269-77. doi: 10.1016/s0022-0736(83)80006-5. PMID: 6619702

Therapy

Nakamura S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nohara Y, Kono S, Nakao E, Sakaue A, Tsuru T, Morikawa N, Fukumoto Y
J Cardiol 2017 Oct;70(4):353-358. Epub 2017 Jan 18 doi: 10.1016/j.jjcc.2016.12.004. PMID: 28109825
Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ
Clin Endocrinol (Oxf) 2007 Feb;66(2):235-45. doi: 10.1111/j.1365-2265.2006.02715.x. PMID: 17223994
Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, Kanter RJ, Rice H, Chen YT, Kishnani PS
Genet Med 2006 May;8(5):297-301. doi: 10.1097/01.gim.0000195896.04069.5f. PMID: 16702879
Evens RP, Fraser DG, Ludden TM, Sutherland EW 3rd
Am J Hosp Pharm 1980 Feb;37(2):232-5. PMID: 7361796

Prognosis

Nakamura S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nohara Y, Kono S, Nakao E, Sakaue A, Tsuru T, Morikawa N, Fukumoto Y
J Cardiol 2017 Oct;70(4):353-358. Epub 2017 Jan 18 doi: 10.1016/j.jjcc.2016.12.004. PMID: 28109825

Clinical prediction guides

Nakamura S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nohara Y, Kono S, Nakao E, Sakaue A, Tsuru T, Morikawa N, Fukumoto Y
J Cardiol 2017 Oct;70(4):353-358. Epub 2017 Jan 18 doi: 10.1016/j.jjcc.2016.12.004. PMID: 28109825
Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ
Clin Endocrinol (Oxf) 2007 Feb;66(2):235-45. doi: 10.1111/j.1365-2265.2006.02715.x. PMID: 17223994
Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, Kanter RJ, Rice H, Chen YT, Kishnani PS
Genet Med 2006 May;8(5):297-301. doi: 10.1097/01.gim.0000195896.04069.5f. PMID: 16702879
Evens RP, Fraser DG, Ludden TM, Sutherland EW 3rd
Am J Hosp Pharm 1980 Feb;37(2):232-5. PMID: 7361796

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...